Veru (NASDAQ:VERU) Posts Quarterly Earnings Results

Veru (NASDAQ:VERU) issued its quarterly earnings data on Wednesday. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.21, FiscalAI reports.

Here are the key takeaways from Veru’s conference call:

• FDA meeting gave regulatory clarity for enobosarm with two potential approval pathways (≥5% incremental placebo‑corrected weight loss at 52 weeks or demonstration of clinically meaningful preservation/improvement in physical function), and confirmed enobosarm 3 mg as an acceptable dose for development.
• Veru plans to start the double‑blind Phase 2b PLATEAU study this quarter in ~200 patients ≥65 years on semaglutide, with a 68‑week primary endpoint for percent change in body weight and an interim DEXA analysis of lean/fat mass at 34 weeks.
• The FDA’s Dec 2025 decision that total hip BMD by DEXA can be a validated surrogate endpoint could provide an alternate approval route for enobosarm in postmenopausal women on GLP‑1 therapy, and preclinical data show enobosarm increases BMD.
• Balance sheet improved after an October 2025 underwritten offering: net proceeds ~$23.4 million and cash, cash equivalents and restricted cash of $33.0 million, which management says should fund operations through the PLATEAU interim analysis.
• The company remains unprofitable with a Q1 net loss of $5.3 million (26¢/share), negative operating cash flow (used $6.2 million in the quarter), and continued development risk ahead of pivotal studies.

Veru Stock Up 1.7%

Shares of NASDAQ VERU traded up $0.04 during trading hours on Wednesday, hitting $2.35. The company had a trading volume of 79,155 shares, compared to its average volume of 122,508. Veru has a 1-year low of $2.10 and a 1-year high of $7.40. The stock has a market capitalization of $37.72 million, a P/E ratio of -1.07 and a beta of -1.42. The firm’s 50 day moving average is $2.43 and its 200-day moving average is $3.11.

Analyst Ratings Changes

Several brokerages have recently commented on VERU. Canaccord Genuity Group assumed coverage on Veru in a research report on Thursday, December 18th. They issued a “buy” rating and a $25.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Veru in a research note on Wednesday, January 21st. Oppenheimer reiterated an “outperform” rating on shares of Veru in a research note on Thursday, December 18th. Finally, Wall Street Zen lowered shares of Veru from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $22.50.

Institutional Investors Weigh In On Veru

A number of large investors have recently bought and sold shares of the company. Marshall Wace LLP bought a new stake in Veru during the 2nd quarter worth approximately $220,000. Osaic Holdings Inc. lifted its position in shares of Veru by 11.9% during the 2nd quarter. Osaic Holdings Inc. now owns 262,820 shares of the company’s stock valued at $152,000 after acquiring an additional 27,954 shares during the period. Qube Research & Technologies Ltd acquired a new stake in shares of Veru in the 2nd quarter valued at about $152,000. Sender Co & Partners Inc. increased its holdings in shares of Veru by 82.8% during the second quarter. Sender Co & Partners Inc. now owns 238,231 shares of the company’s stock valued at $139,000 after acquiring an additional 107,911 shares in the last quarter. Finally, Raymond James Financial Inc. raised its holdings in Veru by 48.3% during the second quarter. Raymond James Financial Inc. now owns 206,405 shares of the company’s stock worth $120,000 after buying an additional 67,178 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors and hedge funds.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.